List of Excipients in Branded Drug LAMIVUDINE AND ZIDOVUDINE

Generic Drugs Containing LAMIVUDINE AND ZIDOVUDINE

Company	Ingredient	NDC	Excipient
Rebel Distributors Corp	lamivudine and zidovudine	21695-996	CELLULOSE, MICROCRYSTALLINE
Rebel Distributors Corp	lamivudine and zidovudine	21695-996	HYPROMELLOSE 2910
Rebel Distributors Corp	lamivudine and zidovudine	21695-996	MAGNESIUM STEARATE
Rebel Distributors Corp	lamivudine and zidovudine	21695-996	POLYETHYLENE GLYCOL 400
Rebel Distributors Corp	lamivudine and zidovudine	21695-996	POLYSORBATE 80

What are the Most Frequently-Used Excipients in LAMIVUDINE AND ZIDOVUDINE?

# Of NDCs	Excipient
22	CELLULOSE, MICROCRYSTALLINE
2	DIBASIC CALCIUM PHOSPHATE DIHYDRATE
5	HYPROMELLOSE
6	HYPROMELLOSE 2910
13	HYPROMELLOSES

Lamivudine and Zidovudine Excipient Strategy and Commercial Opportunities

Last updated: August 12, 2026

Lamivudine/zidovudine is a mature, off-patent fixed-dose combination with limited premium pricing but continuing demand in generic, public-sector, and selected HIV treatment markets. The commercial opportunity is strongest in low-cost tablets, pediatric or dispersible presentations, private-label supply, and regional tenders rather than in a new branded product.

The standard adult strength is 150 mg lamivudine and 300 mg zidovudine per tablet. The main formulation challenge is achieving content uniformity and dissolution for two active pharmaceutical ingredients with different dose ratios, particle properties, stability profiles, and pharmacokinetic requirements. A compact excipient system based on microcrystalline cellulose, a superdisintegrant, a glidant, and a lubricant is commercially attractive if it meets bioequivalence, stability, and manufacturing requirements.

What is the regulatory and commercial status of lamivudine/zidovudine?

Lamivudine/zidovudine was developed as Combivir and approved by the U.S. Food and Drug Administration in 1997 under NDA 020564. The product contains 150 mg lamivudine and 300 mg zidovudine in a film-coated tablet. FDA-approved generic versions are available through abbreviated new drug applications and are listed in the Orange Book under the relevant reference product framework (FDA, 1997; FDA, 2024a).

The product is a small-molecule fixed-dose combination, not a biologic. Biosimilar regulation does not apply. Generic manufacturers compete through ANDA approval, manufacturing cost, supply reliability, regulatory reach, and tender pricing.

Attribute	Lamivudine/zidovudine
Active ingredients	Lamivudine 150 mg; zidovudine 300 mg
Dosage form	Immediate-release, film-coated tablet
Reference product	Combivir
Original innovator	Glaxo Wellcome, now within the GSK/ViiV ecosystem
U.S. approval	1997
FDA pathway for generics	ANDA
Biosimilar exposure	None
Primary markets	Generic HIV treatment, public procurement, selected private markets
Current commercial position	Mature, price-sensitive, secondary-line or legacy regimen

Clinical use has declined in many high-income markets because current HIV guidelines generally favor tenofovir-based or other newer regimens with better tolerability, resistance profiles, or dosing convenience. Zidovudine remains relevant in certain clinical settings, including pregnancy-related protocols, pediatric treatment, resource-limited settings, and patients for whom alternative nucleoside reverse transcriptase inhibitors are unsuitable (U.S. Department of Health and Human Services, 2024; World Health Organization, 2021).

What excipients are used in lamivudine/zidovudine tablets?

The reference tablet uses a conventional solid oral excipient platform. Public product information identifies excipients including microcrystalline cellulose, sodium starch glycolate, colloidal silicon dioxide, and magnesium stearate. Film-coating components can vary by manufacturer and may include hypromellose, titanium dioxide, polyethylene glycol, and other approved coating materials (DailyMed, 2024).

The exact qualitative and quantitative composition of a generic product is proprietary. A generic applicant does not need to copy the reference formulation, but the selected excipients must support pharmaceutical equivalence, bioequivalence, stability, manufacturability, and acceptable labeling.

Functional role of the principal excipients

Excipient class	Typical function	Relevance to the combination
Microcrystalline cellulose	Diluent, dry-binder, compressibility aid	Supports tablet strength and direct compression
Sodium starch glycolate or croscarmellose sodium	Superdisintegrant	Promotes rapid breakup and dissolution
Colloidal silicon dioxide	Glidant, flow aid, moisture scavenger	Improves blend flow and may reduce segregation
Magnesium stearate	Lubricant	Reduces ejection force and tooling adhesion
Hypromellose	Film former	Provides mechanical protection and appearance
Polyethylene glycol	Coating plasticizer	Reduces coating brittleness
Titanium dioxide or approved colorant	Opacifier or colorant	Supports product identification and light protection
Mannitol or lactose	Alternative diluent	May improve mouthfeel or compactability in pediatric products

Lamivudine and zidovudine are both sufficiently potent for conventional tablet manufacture, but the 1:2 active ratio creates a blend-uniformity risk. The higher zidovudine load dominates tablet mass, while lamivudine must remain uniformly distributed at the lower concentration. Particle-size mismatch, density differences, electrostatic charging, and segregation during hopper transfer can produce out-of-specification content-uniformity results.

How should an excipient strategy be designed for this fixed-dose combination?

A robust formulation should begin with a quality target product profile rather than with direct imitation of the reference tablet. The target profile should include:

• Immediate drug release.
• Uniform lamivudine and zidovudine content.
• Adequate tablet hardness with low friability.
• Consistent disintegration after long-term storage.
• Resistance to humidity-related degradation.
• Compatibility with high-throughput compression.
• Acceptable tablet size for chronic twice-daily administration.
• Film protection against abrasion, light, and handling damage.

Direct compression versus wet granulation

Direct compression can provide the lowest manufacturing cost and the shortest process, but it requires well-controlled API particle-size distributions and strong flow characteristics. A typical direct-compression platform could use microcrystalline cellulose as the primary diluent, a superdisintegrant at a controlled level, colloidal silicon dioxide for flow, and magnesium stearate for lubrication.

Wet granulation may be preferable if the APIs have poor flow, high segregation risk, or inadequate compactability. It can improve blend uniformity and tablet strength, but it introduces additional water, drying, process validation, and stability considerations. Zidovudine-containing products should be assessed carefully for moisture exposure and thermal stress during granulation and drying.

A practical development sequence is:

1. Characterize API particle size, bulk density, moisture, compressibility, and electrostatic behavior.
2. Compare direct compression with dry granulation and aqueous or nonaqueous wet granulation.
3. Measure blend uniformity at multiple blender and hopper locations.
4. Optimize lubrication time because excessive magnesium stearate can slow dissolution and reduce tablet strength.
5. Evaluate dissolution using discriminating conditions, not only a single routine medium.
6. Confirm stability under ICH long-term and accelerated conditions (ICH, 2003; ICH, 2009).

Excipient selection priorities

The strongest commercial formulation normally uses excipients with broad regulatory acceptance, multiple qualified suppliers, and established compendial grades. This reduces supply interruption and supports submissions in multiple jurisdictions.

Microcrystalline cellulose is attractive because it is widely available and compatible with direct compression. Sodium starch glycolate is a low-cost disintegrant with broad use in immediate-release tablets. Croscarmellose sodium can provide an alternative where faster or more robust disintegration is needed. Crospovidone may be useful when a formulation requires rapid wicking and low swelling, although cost and supplier availability can differ by market.

Magnesium stearate remains the default lubricant, but its level and mixing time require control. Lower lubricant exposure can preserve dissolution performance. Colloidal silicon dioxide can improve flow, but excessive use may increase dusting, affect tablet appearance, or alter blend behavior.

What formulation risks affect commercial development?

The main technical risks are not novel drug-delivery problems. They are execution risks associated with a mature, low-margin product.

Blend uniformity

Lamivudine content uniformity is the most important risk because it is present at half the mass of zidovudine. The development team should control API particle size and use geometric dilution or a validated granulation process. Sampling plans should cover initial blending, transfer, hopper residence, and compression.

Dissolution sensitivity

Over-lubrication, excessive compression force, high tablet hardness, or an inefficient disintegrant can delay dissolution. A formulation that passes a simple quality-control dissolution test may still show scale-up sensitivity. The control strategy should connect excipient grade, lubricant mixing, compression force, disintegration, and dissolution.

Moisture and chemical stability

Packaging selection should be based on stability data rather than formulation convention. High-density polyethylene bottles with a desiccant can be appropriate for multidose products. Alu-Alu or high-barrier blister packaging may offer stronger moisture protection but can increase packaging cost. The optimal choice depends on the target climate zone, distribution network, and tender requirements.

Tablet size and adherence

A 450 mg total active load creates a relatively large tablet once excipients and coating are included. Reducing excipient mass can improve swallowability, but excessive compression or low-diluent formulations may impair robustness. For a chronic HIV medicine, tablet dimensions, scoring, coating smoothness, and packaging convenience have commercial value.

Excipients of concern

Some markets impose restrictions on particular colorants, titanium dioxide, animal-derived materials, or lactose. A globally deployable formulation should use excipients with broad acceptance and avoid unnecessary colors or complex coating systems. A lactose-free, gelatin-free, and low-color formulation can simplify regional registration and procurement.

What formulations are protected or commercially differentiated?

The conventional immediate-release tablet is largely commoditized. The main differentiation opportunities are dosage form, patient segment, packaging, and supply economics rather than strong composition-of-matter protection.

Pediatric and dispersible formulations

Pediatric HIV treatment remains a potential niche. A dispersible tablet or oral solution can address swallowing limitations, but the formulation must manage:

• Zidovudine bitterness.
• Lamivudine taste.
• Dose flexibility.
• Rapid dispersion in a small volume of water.
• Chemical and microbial stability for liquids.
• Acceptable excipient exposure in infants and children.

Mannitol, selected sweeteners, flavor systems, and taste-masking polymers may improve pediatric acceptability. Oral liquids require preservatives, flavoring systems, and tighter microbial controls, which can raise cost and stability risk. A dispersible tablet may offer a better balance between usability and shelf life.

Scored and smaller-dose presentations

A scored tablet or lower-strength presentation could support dose adjustment, although splitting performance must be validated. Dose flexibility is particularly relevant in pediatric and weight-based treatment. A smaller tablet can also improve acceptability in markets where adult patients have difficulty swallowing large tablets.

Heat- and humidity-resistant packaging

A formulation with a high-barrier blister and documented stability in hot and humid conditions can create procurement value. Public-sector buyers often prioritize shelf life, shipping durability, and predictable availability. Packaging differentiation may therefore be more commercially meaningful than a novel excipient claim.

When does lamivudine/zidovudine lose exclusivity?

The principal U.S. patent and regulatory exclusivity periods for lamivudine/zidovudine have expired. The product is now subject to generic competition, and no biosimilar pathway or biologic exclusivity applies. Current commercial barriers are therefore regulatory approval, manufacturing compliance, product quality, supply reliability, and market access rather than basic patent exclusivity.

Orange Book status

The FDA Orange Book identifies Combivir under NDA 020564 and lists approved generic equivalents where applicable. Orange Book status can change as applicants, therapeutic-equivalence codes, and marketing status are updated. The practical implication is that a new manufacturer would generally pursue an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the reference product (FDA, 2024a).

Paragraph IV and litigation exposure

Paragraph IV litigation risk is comparatively limited for a mature product whose key exclusivity periods have expired. A new ANDA applicant still must evaluate any active Orange Book-listed patents, pediatric extensions, exclusivity codes, and product-specific litigation records at the time of filing. A formulation that uses non-infringing excipients does not eliminate risk from active method-of-use or formulation claims, although the remaining exposure is likely narrower than for a recently approved branded product.

What generic entry risks exist for lamivudine/zidovudine?

Generic entry is technically feasible, but commercial entry can be difficult because the product competes in a price-sensitive market with declining use in some guideline-driven treatment settings.

Risk	Commercial effect	Mitigation
Low selling price	Limits return on formulation investment	Use a simple, scalable excipient system
Declining first-line use	Reduces market volume	Target tenders, pediatric use, and selected regional markets
API price volatility	Compresses gross margin	Dual-source APIs and qualify alternate grades
Supply interruptions	Can trigger lost tenders	Maintain safety stock and qualified suppliers
Variable guideline use	Creates demand uncertainty	Track national HIV protocols and procurement forecasts
Quality failures	Can remove product from tenders	Use process capability and stability-driven controls
Large tablet size	May reduce adherence	Optimize tablet mass, coating, and scoring
Pediatric taste	Limits patient acceptance	Develop dispersible or taste-masked formats

The most credible launch scenarios are a low-cost adult tablet, a public-sector tender product, and a pediatric dispersible tablet. A premium branded reformulation would face a weak value proposition unless it solves a clear adherence, pediatric, or supply problem.

Which companies and channels are most relevant?

Competition comes from generic manufacturers with HIV portfolios, contract manufacturers, regional firms, and public-sector suppliers. The relevant commercial channels include:

• National HIV procurement programs.
• Global Fund-supported tenders.
• PEPFAR-related procurement channels.
• WHO-prequalified or quality-assured suppliers.
• Hospital and institutional purchasing.
• Private pharmacies in markets where lamivudine/zidovudine remains guideline-supported.
• Licensing and private-label arrangements.

WHO prequalification or other stringent quality-assurance pathways can materially expand access to institutional procurement. The regulatory strategy should align formulation development with the target market. A U.S. ANDA alone may not provide access to African, Asian, or Latin American tenders, where local registration, WHO prequalification, stability data, or in-country representation may be required (WHO, 2021; WHO, 2023).

How strong is the patent estate for lamivudine/zidovudine?

The patent estate is weak as a commercial barrier because the product is mature and genericized. The principal value lies in manufacturing know-how, process control, formulation robustness, pediatric dosage-form design, packaging, and market access.

Potentially protectable improvements could include:

• A dispersible tablet with defined dispersion time.
• A taste-masked pediatric formulation.
• A low-mass direct-compression formulation.
• A moisture-protective coating system.
• A stable liquid formulation.
• A manufacturing process that improves content uniformity.
• A specific excipient ratio linked to dissolution or stability.
• A packaging and dosing system for pediatric use.

These claims would need a meaningful technical effect and appropriate claim scope. A patent directed only to routine substitution of one conventional disintegrant for another would face validity and enforceability concerns.

What licensing opportunities exist?

Licensing opportunities are more likely to involve manufacturing and distribution rights than core drug patents. A rights holder could license:

• Regional commercialization.
• Local packaging or secondary manufacturing.
• Pediatric dosage-form technology.
• WHO-prequalified supply.
• Government tender participation.
• API and finished-dose supply.
• Private-label distribution.

A commercially useful deal would typically depend on guaranteed supply volumes, registration ownership, pharmacovigilance obligations, quality agreements, and tender economics. Royalty-heavy structures are difficult to support in a low-price generic market. Territory-specific supply agreements, milestone payments for registration, or minimum-volume commitments are more plausible than high upfront licensing fees.

What is the best excipient and commercial strategy?

The strongest base-case strategy is a conventional, globally acceptable immediate-release tablet using widely sourced excipients and a process selected around blend uniformity. The product should avoid unnecessary formulation complexity.

A practical target is:

1. Direct compression if API flow and segregation data support it.
2. Dry granulation or wet granulation if content uniformity or compactability is inadequate.
3. Microcrystalline cellulose as the principal diluent.
4. Sodium starch glycolate, croscarmellose sodium, or crospovidone as the disintegrant after comparative screening.
5. Controlled colloidal silicon dioxide and magnesium stearate levels.
6. A simple film coat with broad regulatory acceptance.
7. High-barrier packaging selected for the intended climate zone.
8. A parallel pediatric program only if target-market data supports demand.

The adult tablet should be optimized for cost and reliable supply. Pediatric development should be treated as a separate product opportunity, not as a minor variation of the adult formulation.

Key Takeaways

• Lamivudine/zidovudine is a mature, off-patent small-molecule fixed-dose combination.
• The standard product is a 150 mg/300 mg immediate-release film-coated tablet.
• The core excipient platform is conventional: microcrystalline cellulose, superdisintegrant, colloidal silicon dioxide, magnesium stearate, and a film coat.
• Blend uniformity, especially for lamivudine, is the principal formulation risk.
• Direct compression offers the strongest cost position if API flow and segregation are controlled.
• Pediatric dispersible tablets, taste-masked products, and heat-resistant packaging offer the clearest differentiation.
• Biosimilar risk is irrelevant; generic ANDA and national registration pathways control market entry.
• Patent barriers are weak, while supply reliability, quality assurance, tender access, and manufacturing economics determine commercial success.
• Premium pricing is difficult without a clinically relevant pediatric, adherence, or stability advantage.
• Licensing opportunities are more likely to involve regional distribution, private label, manufacturing, or tender access than core molecule rights.

FAQs

Can lamivudine and zidovudine be formulated in one tablet?

Yes. The approved fixed-dose combination demonstrates commercial and regulatory feasibility. The formulation must control segregation, lamivudine content uniformity, dissolution, and stability.

Is a liquid lamivudine/zidovudine product commercially attractive?

It can be attractive for pediatric markets, but liquids introduce taste, preservative, microbial, packaging, and stability challenges. A dispersible tablet may provide a lower-cost alternative with better shelf life.

Which excipient is most important for dissolution?

The superdisintegrant is a major determinant, but dissolution also depends on lubricant concentration, lubricant mixing time, compression force, tablet porosity, and API particle size.

Does a generic manufacturer need to use the same excipients as Combivir?

No. A generic manufacturer may use different excipients if the product meets pharmaceutical equivalence, bioequivalence, quality, stability, and labeling requirements.

Can a new excipient combination obtain patent protection?

Potentially, but only if the combination produces a credible and non-obvious technical benefit, such as improved stability, dissolution, content uniformity, taste masking, or pediatric usability.

References

1. DailyMed. (2024). Combivir: Lamivudine and zidovudine tablet, film coated. U.S. National Library of Medicine.

2. Food and Drug Administration. (1997). Combivir approval information, NDA 020564. U.S. Department of Health and Human Services.

3. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

4. International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products.

5. International Council for Harmonisation. (2009). Q8(R2): Pharmaceutical development.

6. U.S. Department of Health and Human Services. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV.

7. World Health Organization. (2021). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: Recommendations for a public health approach.

8. World Health Organization. (2023). WHO prequalification of medicines programme: Guidance and quality-assurance requirements for HIV medicines.